NEW YORK – Liquid biopsy testing firm Inivata said on Wednesday that it has molecularly profiled the first lung cancer patients using its InVisionFirst-Lung ctDNA panel within the Phase II ALKALINE trial of lorlatinib (Pfizer's Lorviqua in Europe and Lobrena in the US).